Will This Company's Artificial Pancreas Disrupt the Insulin Pump Market?

Approximately, 347 million people worldwide currently suffer from diabetes, including 8.3% of Americans. The CDC believes that as many as one in every three adults in America will have diabetes by 2050, a sobering figure that reminds us that despite all the treatments we have for the disease, there is still no cure. However, technological advances have steadily improved the lives of diabetics by making the disease more manageable.

Medtronic's artificial pancreas
Medtronic (NYSE: MDT  ) recently made history when its wearable artificial pancreas, the first of its kind, was approved by the Food and Drug Administration. The device is designed for type 1 diabetics whose bodies cannot produce any insulin, in contrast to type 2 diabetes, which is characterized by insulin deficiency. Approximately, 5% to 10% of diabetics are classified as type 1.

Type 1 diabetics need to monitor their blood sugar levels continuously throughout the day with pinpricks and insulin injections. To decrease this burden, companies have made wearable insulin pumps and continuous glucose monitoring devices, but the two devices must be used independently.

Medtronic's MinMed 530G. Source: Company website.

Medtronic's artificial pancreas, the MiniMed 530G, is different. In a clinical trial, patients were found to be 31.8% less likely to suffer acute events while wearing the device. The device can also automatically stop insulin delivery when glucose levels reach a low preset threshold.

Last quarter, Medtronic's diabetes group reported revenue of $369 million, a 1% year-over-year gain that accounted for 9% of the company's top line. The segment's top-selling products were its Veo insulin pump and its Enlite continuous glucose monitoring sensor. Medtronic stated that insulin pump sales in the United States had declined due to the anticipated launch of the MiniMed 530G.

Letting bygones be bygones
Medtronic also recently signed a cross-licensing deal with Insulet  (NASDAQ: PODD  ) , which it took to court last year over the alleged patent infringement of its MiniMed patents. Insulet's primary product is the OmniPod Insulin Management System, which features a disposable, tube-free pod that can be worn on the body for three days at a time. The device communicates wirelessly with a handheld personal diabetes manager. Unlike Medtronic's MiniMed 530G, however, it is a manually operated system.

Insulet's OmniPod. Source: Company website.

Since Insulet is a pure play on "smart" insulin pumps, compared to Medtronic's diversified medical device operations, it has generated a lot of excitement among investors. The stock is up more than 70% over the past 12 months, although the company has yet to post a profit. Insulet's revenue rose 18% year over year last quarter.

Others aren't that far behind
The game-changing nature of Medtronic's artificial pancreas hasn't gone unnoticed in the medical device industry. The market for glucose monitors and insulin pumps generates $2.4 billion in annual revenue -- which could be disrupted by Medtronic's new device.

DexCom (NASDAQ: DXCM  ) , which manufactures continuous glucose monitors, could be hit by this technological shift. The company has built its entire business on extended use continuous glucose monitors, the latest of which can be used continuously for up to seven days. Like Insulet, expectations for DexCom are high, and shares have risen 87% over the past 12 months. DexCom is also unprofitable, although its annual revenue has steadily risen 150% over the past three years. Rather than create its own artificial pancreas; however, DexCom is helping Johnson & Johnson (NYSE: JNJ  ) create one.

Johnson & Johnson, whose medical device business accounted for 40% of its revenue last quarter, has also been developing its own artificial pancreas, Animas. The device is integrated with DexCom's continuous glucose monitoring technology, and is expected to be approved and launched next year.

Last quarter, the diabetes care segment of J&J's medical device business reported a 12.5% year-over-year decline in revenue, and only accounted for 8.2% of the segment's total sales. The diabetes care business was a laggard in the medical device segment, which grew 9.6% last quarter -- a decline that Animas could rectify.

The Foolish bottom line
It isn't surprising that Medtronic was the first company to create the first artificial pancreas. After all, this is the same company which created the first battery-powered external pacemaker in 1957 and introduced the first insulin pump in 1983.

If Medtronic can capitalize on its head start over J&J and DexCom over the next few months to establish a firm foothold in medical facilities across the country, the MiniMed 530G could significantly boost its lagging diabetes business and improve the lives of millions of diabetics.

Game-changing stocks in the cancer space
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Editor's Note: A previous version of this article included a sentence that didn't clearly explain the MiniMed 530G's technology. The Fool regrets the error.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 06, 2013, at 4:09 AM, apgrovas wrote:

    Being a type 1 diabetic, I have to say that I find it beyond annoying that the marketing and pressheads are all over calling Medtronic's device an artificial pancreas. Honestly, an artificial pancreas has to be a control loop that increases and decreases the amount of injected insulin based on glucose measurements to keep tight control on a patient's blood glucose. All Medtronic's device does is stop insulin delivery from its pump when the continuous glucose monitor detects blood glucose falling below a defined threshold ...this is SERIOUSLY short of being an artificial pancreas. Both the press and Medtronic's marketing people should stop calling it that, for they are doing so purely for economic gain and nothing else. Please, call a device an artificial pancreas when it truly is one and it truly acts as the tight control loop that the pancreas is. Until then, don't insult our intelligence and spare us lies like this, please.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2664721, ~/Articles/ArticleHandler.aspx, 12/18/2014 8:37:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement